- In November 2021, I-MAB Biopharma Co., Ltd. entered into a collaboration with Jumpcan Pharmaceutical Group for the development & commercialization of eftansomatropin alfa (TJ101) in China. TJ101 is a long-acting recombinant human growth hormone, which is currently under phase 3 clinical trial for the treatment of pediatric growth hormone deficiency. This collaboration is expected to strengthen its position in the hormone replacement therapy market.
- In February 2023, Korea’s Ministry of Food and Drug Safety approved Pfizer’s NGENLA for the treatment of growth hormone deficiency. Some of the key players in the global hormone replacement therapy market include.
